Science (New York, N.Y.) · 2026
DNA origami vaccines program antigen-focused germinal centers.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Romanov Anna, Knappe Grant A, Ronsard Larance, Cottrell Christopher A, Zhang Yiming J, Suh Heikyung, Duhamel Lauren, Omer Marjan, Chapman Asheley P, Spivakovsky Katie, Skog Patrick, Flynn Claudia T, Lee Jeong Hyun, Kalyuzhniy Oleksandr, Liguori Alessia, Parsons Molly F, Lewis Vanessa R, Canales Josue, Reizis Boris, Tingle Ryan D, Schiffner Torben, Schief William R, Lingwood Daniel, Bathe Mark, Irvine Darrell J
Аннотация
Priming rare subdominant precursor B cells in germinal centers (GCs) is a central goal of vaccination to generate broadly neutralizing antibodies (bnAbs) against HIV. Multivalent immunogen display on protein nanoparticle scaffolds can promote such responses, but it also generates scaffold-specific B cells that could theoretically limit bnAb precursor expansion in GCs. We rationally designed DNA origami-based virus-like particles (DNA-VLPs) displaying a germline-targeting HIV envelope protein immunogen, which elicited no scaffold-specific antibody responses. Compared with a state-of-the-art clinical protein nanoparticle, these DNA-VLPs increased the expansion of epitope-specific GC B cells relative to off-target B cells and enhanced expansion of bnAb-lineage B cells in a humanized mouse model of CD4 binding site priming. Thus, minimizing off-target responses enhances bnAb priming and indicates that DNA-VLPs are a promising vaccine platform.
Предметные рубрики MeSH
AnimalsHumansMiceAIDS VaccinesAntibodies, NeutralizingB-LymphocytesBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusEpitopesGerminal CenterHIV AntibodiesHIV InfectionsHIV-1Vaccines, DNAVaccines, Virus-Like ParticleDNA NanostructuresDisease Models, AnimalFemaleMice, Inbred C57BL